Civic Intelligence

Global Health Solutions Inc.

990 • Fiscal year 2018 • EIN 20-3674498

Sep 01, 2017 to Aug 31, 2018 • Filed on Jul 01, 2019

Organization Profilewww.taskforce.org
325 Swanton WayDecatur, GA 30030-3001

(404) 592-1430

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

Score unavailable

No value available

Liabilities-to-assets requires both liabilities and assets on this filing.

Source year 2018

Liabilities / Revenue

2nd percentile

0.00x

Tied with the lowest-debt nonprofits in its peer group.

2018 filings • 501(c)3 • $1B+ nonprofits • Source year 2018

Net Margin

15th percentile

0.0%

Higher net margin than 15% of similar nonprofits.

2018 filings • 501(c)3 • $1B+ nonprofits • Source year 2018

Top Officer Pay

4th percentile

$342,303

Higher top officer pay than 4% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

2018 filings • 501(c)3 • $1B+ nonprofits • Source year 2018

Asset Growth

Score unavailable

No value available

A valid growth rate could not be computed from the available filing history.

Annualized from 2017 to 2018

Revenue Growth

5th percentile

-18%

Faster revenue growth than 5% of similar nonprofits.

2018 filings • 501(c)3 • $1B+ nonprofits • Annualized from 2017 to 2018

Balance Sheet
Liabilities / AssetsScore unavailable

Assets

Flat

$0

Flat from 2017

Net Assets

Flat

$0

Flat from 2017

Liabilities

Flat

$0

Flat from 2017

Revenue And Expenses
Liabilities / Revenue2nd percentileNet Margin15th percentile

Revenue

Down

$2,143,738,652

Down $475,373,779 (-18%) from 2017

Expenses

Down

$2,143,738,652

Down $475,373,779 (-18%) from 2017

Net Income

Flat

$0

Flat from 2017

Historical Trend

Balance Sheet Trend

Asset GrowthScore unavailable

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$3.0M$2.0M$1.0M$0Assets 2010: $2,355,762Liabilities 2010: $0Net Assets 2010: $2,355,7622010Assets 2011: $2,355,057Liabilities 2011: $0Net Assets 2011: $2,355,0572011Assets 2012: $2,354,867Liabilities 2012: $0Net Assets 2012: $2,354,8672012Assets 2013: $2,354,585Liabilities 2013: $0Net Assets 2013: $2,354,5852013Assets 2014: $2,354,303Liabilities 2014: $0Net Assets 2014: $2,354,3032014Assets 2015: $2,354,008Liabilities 2015: $0Net Assets 2015: $2,354,0082015Assets 2016: $0Liabilities 2016: $0Net Assets 2016: $02016Assets 2017: $0Liabilities 2017: $0Net Assets 2017: $02017Assets 2018: $0Liabilities 2018: $0Net Assets 2018: $02018Assets 2019: $0Liabilities 2019: $0Net Assets 2019: $02019Assets 2020: $0Liabilities 2020: $0Net Assets 2020: $02020Assets 2021: $0Liabilities 2021: $0Net Assets 2021: $02021Assets 2022: $0Liabilities 2022: $0Net Assets 2022: $02022Assets 2023: $0Liabilities 2023: $0Net Assets 2023: $02023Assets 2024: $0Liabilities 2024: $0Net Assets 2024: $02024

Highlighted filing

2018

Assets$0
Liabilities$0
Net Assets$0
Open 2018 Filing

Operations Trend

Revenue Growth5th percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$4.0B$3.0B$2.0B$1.0B$0-$1.0BExpenses 2010: $1,120,650,0812010Expenses 2011: $1,131,365,2102011Expenses 2012: $1,634,124,1552012Revenue 2013: $1,574,497,941Expenses 2013: $1,574,498,224Net Income 2013: -$2832013Revenue 2014: $1,790,885,365Expenses 2014: $1,790,885,647Net Income 2014: -$2822014Revenue 2015: $1,609,270,608Expenses 2015: $1,609,270,903Net Income 2015: -$2952015Revenue 2016: $3,126,468,204Expenses 2016: $3,128,822,213Net Income 2016: -$2,354,0092016Revenue 2017: $2,619,112,431Expenses 2017: $2,619,112,431Net Income 2017: $02017Revenue 2018: $2,143,738,652Expenses 2018: $2,143,738,652Net Income 2018: $02018Revenue 2019: $2,522,088,710Expenses 2019: $2,522,088,710Net Income 2019: $02019Revenue 2020: $846,866,932Expenses 2020: $846,866,932Net Income 2020: $02020Revenue 2021: $961,202,345Expenses 2021: $961,202,345Net Income 2021: $02021Revenue 2022: $632,371,996Expenses 2022: $632,371,996Net Income 2022: $02022Revenue 2023: $628,809,066Expenses 2023: $628,809,066Net Income 2023: $02023Revenue 2024: $511,468,181Expenses 2024: $511,468,181Net Income 2024: $02024

Highlighted filing

2018

Revenue$2,143,738,652
Expenses$2,143,738,652
Net Income$0
Open 2018 Filing
Jump To
Filing Snapshot
Filing Period
Sep 1, 2017 to Aug 31, 2018
Signed
Jul 1, 2019
Return Version
2017v2.0
Gross Receipts
$2,143,738,652
Mission and Program Overview

Mission

As a supporting organization, support the global health efforts of The Task Force for Global Health, Inc. by principally receiving donated phamaceuticals and shipping them to designated countries for the treatment of blinding trachoma, river blindness and vaccine preventable diseases.

As a supporting organization, provide support to the global health initiatives of The Task Force for Global Health,Inc.

Balance Sheet Detail
LineBeginningEndChange
Assets
Cash and Non-Interest-Bearing Accounts$0$0→ $0
Savings and Temporary Cash Investments$0$0→ $0
Accounts Receivable$0$0→ $0
Other Notes and Loans Receivable, Net$0$0→ $0
Pledges and Grants Receivable$0$0→ $0
Receivable From Disqualified Prsn$0$0→ $0
Receivables From Officers Etc$0$0→ $0
Investments Other Securities$0$0→ $0
Investments Program Related$0$0→ $0
Investments in Publicly Traded Securities$0$0→ $0
Intangible Assets$0$0→ $0
Inventories for Sale or Use$0$0→ $0
Loans From Officers Directors$0$0→ $0
Prepaid Expenses and Deferred Charges$0$0→ $0
Other Assets Total$0$0→ $0
Total Assets$0$0→ $0
Liabilities
Accounts Payable and Accrued Expenses$0$0→ $0
Grants Payable$0$0→ $0
Mortgage Notes Payable Secured by Investment Property$0$0→ $0
Unsecured Notes Loans Payable$0$0→ $0
Other Liabilities$0$0→ $0
Deferred Revenue$0$0→ $0
Escrow Account Liability$0$0→ $0
Tax Exempt Bond Liabilities$0$0→ $0
Total Liabilities$0$0→ $0
Net Assets / Fund Balance
Permanently Rstr Net Assets$0$0→ $0
Temporarily Rstr Net Assets$0$0→ $0
Unrestricted Net Assets$0$0→ $0
Total Net Assets Fund Balance$0$0→ $0
Total Liabilities and Net Assets / Fund Balance$0$0→ $0
Compensation and Service Providers
Top Officer Pay4th percentile

Board Members and Trustees

NameTitle
David A RossChairman
Mark L RosenbergChairman
Heather BrooksOfficer
Mark McKinlayOfficer
William P NicholsTreasurer
Revenue and Support

Revenue Composition

Contributions and Grants
$2,143,738,652
Program Service Revenue
$0
Investment Income
$0
Other Revenue
$0
All Other Contributions
$2,143,738,652
Change in Net Assets
$0

Noncash Contribution Practices

Property subject to holding requirements
No
Reviewed unusual noncash gifts
Yes
Third parties used for noncash contributions
No

Noncash Contributions

Contribution TypeContribution CountReported AmountValuation Method
Drugs and Medical Supplies6$2,143,738,652Lower of value by donor or selected pharmacies
Total Noncash Contributions6$2,143,738,652-

Audited Revenue Reconciliation

Revenue per Audited Statements
$2,143,738,652
Revenue Not Reported on Financial Statements
$0
Revenue Not Reported on Form 990
$0
Other Revenue Adjustments
$0
Total Revenue per Audited Statements
$2,143,738,652
Total Revenue per Form 990
$2,143,738,652
Expenses and Functional Allocation

Major Expense Lines

Line ItemAmount
Grants and Similar Amounts Paid$2,143,738,652
Other Expenses$0
Professional Fundraising Fees$0
Salaries, Compensation, and Employee Benefits$0
Total Fundraising Expense$0

Functional Expense Allocation

Line ItemProgramManagementFundraisingTotal
Foreign Grants$2,143,738,652--$2,143,738,652
Total Functional Expenses$2,143,738,652$0$0$2,143,738,652

Audited Expense Reconciliation

Line ItemAmount
Expenses per Audited Statements$2,143,738,652
Total Expenses per Audited Statements$2,143,738,652
Total Expenses per Form 990$2,143,738,652
Expenses Not Reported on Financial Statements$0
Expenses Not Reported on Form 990$0
Other Expense Adjustments$0
International Activity

International Summary

Offices
1
Employees
13
Spending
$2,143,738,652

International Compliance

Foreign grant records maintained
Yes
Activity in boycott countries
No
Foreign corporation ownership
No
Foreign partnership interest
No
Interest in foreign trust
No
Passive foreign investment company interest
No
Transfers to foreign corporations
No

International Activities

RegionActivityServicesOfficesEmployeesSpending
Sub-Saharan AfricaProgram ServicesDonated pharmaceuticals113$2,127,614,405
Middle East and North AfricaProgram ServicesDonated pharmaceuticals00$9,420,840
East Asia and the PacificProgram ServicesDonated pharmaceuticals00$3,230,921
South AsiaProgram ServicesDonated pharmaceuticals00$1,825,579
Europe (including Iceland and Greenland)Program ServicesDonated pharmaceuticals00$1,646,907
Fundraising, Events, and Gaming
Fundraising activities
No
Gaming activities
No
Professional fundraiser used
No

Fundraising and Gaming Totals

Line ItemAmount
Professional Fundraising Fees$0
Political and Lobbying Activity
Political campaign activity
No
Lobbying activity
No
Subject to proxy tax
No
Insider Transactions and Loans

Loans and Receivables

Line ItemBeginningEndChange
Loans from Officers, Directors, Trustees, and Key Employees$0$0→ $0
Receivables from Disqualified Persons$0$0→ $0
Receivables from Officers, Directors, Trustees, and Key Employees$0$0→ $0
Governance and Compliance

Governance Checklist

Compiled or reviewed by an accountant
No
Annual disclosure for covered persons
Yes
Audit committee
Yes
Backup withholding compliance
No
Business relationship with family members
No
Business relationship with organization members
No
Material changes to governing documents
No
Compensation from other sources disclosed
Yes
CEO compensation reviewed
Yes
Other officer compensation reviewed
Yes
Conflict-of-interest policy
Yes
Audited financial statements prepared
Yes
Key decisions subject to board approval
No
Management duties delegated
No

Governance Explanations

Form 990, Part VI, Section B, Line 11B

“Once Form 990 is completed, it is emailed as a pdf file to each board member and officers for their review and comments. They are to notify the organization within five business days with any issues or concerns.”

Form 990, Part VI, Section B, Line 12C

“The organization does not have employees but has officers. At the end of every fiscal year, all officers are required to read and sign all relevant policies.”

Form 990, Part VI, Section B, Line 15

“The organization has no employees. The officers are paid from its related organization where the reviews are done.”

Form 990, Part VI, Section C, Line 19

“The information for three fiscal years is available on the organizations's website together with its Form 990 report.”

Filing and Contact Details

Filer

Filer Name
Global Health Solutions Inc
EIN
20-3674498
Phone
4045921430
Address
325 Swanton Way, Decatur, GA 30030-3001

Signing Officer

Name
William Nichols
Title
Treasurer
Phone
4045921430
Signed
2019-07-01

Organization Details

Principal Officer
William Nichols
Formed
2005
Legal Domicile
Ga
Voting Board Members
4
Independent Board Members
0
Employees
0
Volunteers
0
Supplemental Narrative

Financial Statement Notes

Schedule D, Part X, Line 2

“During December 2017, the President of the United States of America signed into law the Tax Cuts and Jobs Act. Under this Act, maximum corporate tax rates were reduced from 35% to a flat rate of 21%. The Organization's tax liability for any potential unrelated business income should not be significant. There are other changes to the tax law that may affect the Organization, but the magnitude of such changes has not been determined.”

Raw XML AppendixShowing 400 of 612 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990/AccountantCompileOrReviewInd00
IRS990/AccountsPayableAccrExpnssGrp/BOYAmt00
IRS990/AccountsPayableAccrExpnssGrp/EOYAmt00
IRS990/AccountsReceivableGrp/BOYAmt00
IRS990/AccountsReceivableGrp/EOYAmt00
IRS990/ActivitiesConductedPrtshpInd00
IRS990/ActivityOrMissionDesc0As a supporting organization, provide support to the global health initiatives of The Task Force for Global Health,Inc.
IRS990/AllOtherContributionsAmt02143738652
IRS990/AnnualDisclosureCoveredPrsnInd01
IRS990/AuditCommitteeInd01
IRS990/BackupWthldComplianceInd00
IRS990/BenefitsToMembersGrp/TotalAmt00
IRS990/BooksInCareOfDetail/PersonNm0Daniel N Martins
IRS990/BooksInCareOfDetail/PhoneNum04046875620
IRS990/BooksInCareOfDetail/USAddress/AddressLine1Txt0325 Swanton Way
IRS990/BooksInCareOfDetail/USAddress/CityNm0Decatur
IRS990/BooksInCareOfDetail/USAddress/StateAbbreviationCd0GA
IRS990/BooksInCareOfDetail/USAddress/ZIPCd0300303001
IRS990/BusinessRlnWithFamMemInd00
IRS990/BusinessRlnWithOfficerEntInd00
IRS990/BusinessRlnWithOrgMemInd00
IRS990/CashNonInterestBearingGrp/BOYAmt00
IRS990/CashNonInterestBearingGrp/EOYAmt00
IRS990/ChangeToOrgDocumentsInd00
IRS990/CntrctRcvdGreaterThan100KCnt00
IRS990/CollectionsOfArtInd00
IRS990/CompCurrentOfcrDirectorsGrp/TotalAmt00
IRS990/CompDisqualPersonsGrp/TotalAmt00
IRS990/CompensationFromOtherSrcsInd01
IRS990/CompensationProcessCEOInd01
IRS990/CompensationProcessOtherInd01
IRS990/ConflictOfInterestPolicyInd01
IRS990/ConservationEasementsInd00
IRS990/ConsolidatedAuditFinclStmtInd01
IRS990/ContriRptFundraisingEventAmt00
IRS990/CreditCounselingInd00
IRS990/CYBenefitsPaidToMembersAmt00
IRS990/CYContributionsGrantsAmt02143738652
IRS990/CYGrantsAndSimilarPaidAmt02143738652
IRS990/CYInvestmentIncomeAmt00
IRS990/CYOtherExpensesAmt00
IRS990/CYOtherRevenueAmt00
IRS990/CYProgramServiceRevenueAmt00
IRS990/CYRevenuesLessExpensesAmt00
IRS990/CYSalariesCompEmpBnftPaidAmt00
IRS990/CYTotalExpensesAmt02143738652
IRS990/CYTotalFundraisingExpenseAmt00
IRS990/CYTotalProfFndrsngExpnsAmt00
IRS990/CYTotalRevenueAmt02143738652
IRS990/DecisionsSubjectToApprovaInd00
IRS990/DeductibleArtContributionInd00
IRS990/DeductibleNonCashContriInd01
IRS990/DeferredRevenueGrp/BOYAmt00
IRS990/DeferredRevenueGrp/EOYAmt00
IRS990/DelegationOfMgmtDutiesInd00
IRS990/Desc0The International Trachoma Initiative (ITI) has established a unique competitive advantage within the global trachoma community based on its singular focus on trachoma, its credibility as a neutral convener and trusted ally, its flexibility and ability to lead initiatives in support of scale-up, and its role as the sole steward of Pfizer, Inc.'s Zithromax(R) drug donation. ITI fulfills three value-adding roles that contribute to the implementation of the WHO-endorsed SAFE strategy (Surgery, Antibiotic treatment, Facial cleanliness, Environmental improvement , namely: 1) stewardship of the Zithromax(R) drug donation; 2) program delivery strengthening, through operational research, knowledge sharing, capacity building and technical backstopping; and 3) partnership development, through support to the International Coalition for Trachoma Control (ICTC), spearheading WASH/NTD engagement, and mobilizing resources for trachoma. In FY 2018, ITI celebrated 20 years of working for a world free from trachoma and organized just-in-time shipments of over 101.5 million doses of Zithromax(R) to 17 countries, bringing the cumulative total of doses donated since its inception in 1998 to over 810 million doses. ITI continued its data management support for Tropical Data, a free mobile phone-based service to support trachoma programs as they conduct prevalence surveys, providing them with robust data for decision making on where antibiotic treatments are needed and where they can be stopped. ITI's commitment to strong stewardship of the antibiotic donation from Pfizer, coupled with its solid data management and transparent communications, have contributed to remarkable achievements by the global trachoma community in reducing the population at risk of blindness from this preventable disease from an estimated 1.2 billion people in 2000 to 142 million in FY 2018. With just two years left until the World Health Organization's global trachoma elimination goal, ITI will continue to enhance its support, improve its effectiveness, and increase its efficiencies to maximize impact.
IRS990/DescribedInSection501c3Ind01
IRS990/DisregardedEntityInd00
IRS990/DocumentRetentionPolicyInd01
IRS990/DonatedServicesAndUseFcltsAmt00
IRS990/DonorAdvisedFundInd00
IRS990/ElectionOfBoardMembersInd00
IRS990/EmployeeCnt00
IRS990/EngagedInExcessBenefitTransInd00
IRS990/EscrowAccountLiabilityGrp/BOYAmt00
IRS990/EscrowAccountLiabilityGrp/EOYAmt00
IRS990/ExpenseAmt01821698495
IRS990/FamilyOrBusinessRlnInd00
IRS990/FederalGrantAuditRequiredInd00
IRS990/FederatedCampaignsAmt00
IRS990/ForeignActivitiesInd01
IRS990/ForeignFinancialAccountInd00
IRS990/ForeignGrantsGrp/ProgramServicesAmt02143738652
IRS990/ForeignGrantsGrp/TotalAmt02143738652
IRS990/ForeignOfficeInd01
IRS990/Form8282PropertyDisposedOfInd00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt039
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt139
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt239
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt339
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt439
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt01
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt11
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt21
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt31
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt41
IRS990/Form990PartVIISectionAGrp/FormerOfcrDirectorTrusteeInd0X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd0X
IRS990/Form990PartVIISectionAGrp/OfficerInd0X
IRS990/Form990PartVIISectionAGrp/OfficerInd1X
IRS990/Form990PartVIISectionAGrp/OfficerInd2X
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt00
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt10
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt20
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt30
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt40
IRS990/Form990PartVIISectionAGrp/PersonNm0David A Ross
IRS990/Form990PartVIISectionAGrp/PersonNm1William P Nichols
IRS990/Form990PartVIISectionAGrp/PersonNm2Heather Brooks
IRS990/Form990PartVIISectionAGrp/PersonNm3Mark McKinlay
IRS990/Form990PartVIISectionAGrp/PersonNm4Mark L Rosenberg
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt0342303
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt1234914
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt2159179
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt3235466
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt4162999
IRS990/Form990PartVIISectionAGrp/TitleTxt0Chairman
IRS990/Form990PartVIISectionAGrp/TitleTxt1Treasurer
IRS990/Form990PartVIISectionAGrp/TitleTxt2Officer
IRS990/Form990PartVIISectionAGrp/TitleTxt3Officer
IRS990/Form990PartVIISectionAGrp/TitleTxt4Chairman
IRS990/Form990ProvidedToGvrnBodyInd01
IRS990/FormationYr02005
IRS990/FormerOfcrEmployeesListedInd01
IRS990/FSAuditedBasisGrp/ConsolidatedBasisFinclStmtInd0X
IRS990/FSAuditedInd01
IRS990/FundraisingActivitiesInd00
IRS990/FundraisingAmt00
IRS990/GainOrLossGrp/OtherAmt00
IRS990/GainOrLossGrp/SecuritiesAmt00
IRS990/GamingActivitiesInd00
IRS990/GoverningBodyVotingMembersCnt04
IRS990/GovernmentGrantsAmt00
IRS990/GrantAmt00
IRS990/GrantsPayableGrp/BOYAmt00
IRS990/GrantsPayableGrp/EOYAmt00
IRS990/GrantsToDomesticIndividualsGrp/ProgramServicesAmt00
IRS990/GrantsToDomesticIndividualsGrp/TotalAmt00
IRS990/GrantsToDomesticOrgsGrp/ProgramServicesAmt00
IRS990/GrantsToDomesticOrgsGrp/TotalAmt00
IRS990/GrantsToIndividualsInd00
IRS990/GrantsToOrganizationsInd00
IRS990/GrantToRelatedPersonInd00
IRS990/GrossReceiptsAmt02143738652
IRS990/GroupReturnForAffiliatesInd00
IRS990/IncludeFIN48FootnoteInd01
IRS990/IndependentAuditFinclStmtInd00
IRS990/IndependentVotingMemberCnt00
IRS990/IndivRcvdGreaterThan100KCnt00
IRS990/IndoorTanningServicesInd00
IRS990/InfoInScheduleOPartVIInd0X
IRS990/IntangibleAssetsGrp/BOYAmt00
IRS990/IntangibleAssetsGrp/EOYAmt00
IRS990/InventoriesForSaleOrUseGrp/BOYAmt00
IRS990/InventoriesForSaleOrUseGrp/EOYAmt00
IRS990/InvestmentExpenseAmt00
IRS990/InvestmentInJointVentureInd00
IRS990/InvestmentsOtherSecuritiesGrp/BOYAmt00
IRS990/InvestmentsOtherSecuritiesGrp/EOYAmt00
IRS990/InvestmentsProgramRelatedGrp/BOYAmt00
IRS990/InvestmentsProgramRelatedGrp/EOYAmt00
IRS990/InvestmentsPubTradedSecGrp/BOYAmt00
IRS990/InvestmentsPubTradedSecGrp/EOYAmt00
IRS990/IRPDocumentCnt00
IRS990/IRPDocumentW2GCnt00
IRS990/LegalDomicileStateCd0GA
IRS990/LoanOutstandingInd00
IRS990/LoansFromOfficersDirectorsGrp/BOYAmt00
IRS990/LoansFromOfficersDirectorsGrp/EOYAmt00
IRS990/LobbyingActivitiesInd00
IRS990/LocalChaptersInd00
IRS990/MaterialDiversionOrMisuseInd00
IRS990/MembershipDuesAmt00
IRS990/MembersOrStockholdersInd00
IRS990/MethodOfAccountingAccrualInd0X
IRS990/MinutesOfCommitteesInd01
IRS990/MinutesOfGoverningBodyInd01
IRS990/MissionDesc0As a supporting organization, support the global health efforts of The Task Force for Global Health, Inc. by principally receiving donated phamaceuticals and shipping them to designated countries for the treatment of blinding trachoma, river blindness and vaccine preventable diseases.
IRS990/MoreThan5000KToIndividualsInd00
IRS990/MoreThan5000KToOrgInd01
IRS990/MortgNotesPyblScrdInvstPropGrp/BOYAmt00
IRS990/MortgNotesPyblScrdInvstPropGrp/EOYAmt00
IRS990/NetAssetsOrFundBalancesBOYAmt00
IRS990/NetAssetsOrFundBalancesEOYAmt00
IRS990/NetUnrelatedBusTxblIncmAmt00
IRS990/NetUnrlzdGainsLossesInvstAmt00
IRS990/NoncashContributionsAmt02143738652
IRS990/NondeductibleContributionsInd00
IRS990/OfficerMailingAddressInd00
IRS990/OperateHospitalInd00
IRS990/Organization501c3Ind0X
IRS990/OrganizationFollowsSFAS117Ind0X
IRS990/OtherAssetsTotalGrp/BOYAmt00
IRS990/OtherAssetsTotalGrp/EOYAmt00
IRS990/OtherChangesInNetAssetsAmt00
IRS990/OtherLiabilitiesGrp/BOYAmt00
IRS990/OtherLiabilitiesGrp/EOYAmt00
IRS990/OtherRevenueTotalAmt00
IRS990/OtherSalariesAndWagesGrp/TotalAmt00
IRS990/OthNotesLoansReceivableNetGrp/BOYAmt00
IRS990/OthNotesLoansReceivableNetGrp/EOYAmt00
IRS990/OwnWebsiteInd0X
IRS990/PartialLiquidationInd00
IRS990/PayPremiumsPrsnlBnftCntrctInd00
IRS990/PermanentlyRstrNetAssetsGrp/BOYAmt00
IRS990/PermanentlyRstrNetAssetsGrp/EOYAmt00
IRS990/PledgesAndGrantsReceivableGrp/BOYAmt00
IRS990/PledgesAndGrantsReceivableGrp/EOYAmt00
IRS990/PoliticalCampaignActyInd00
IRS990/PrepaidExpensesDefrdChargesGrp/BOYAmt00
IRS990/PrepaidExpensesDefrdChargesGrp/EOYAmt00
IRS990/PrincipalOfficerNm0William Nichols
IRS990/PriorPeriodAdjustmentsAmt00
IRS990/ProfessionalFundraisingInd00
IRS990/ProgSrvcAccomActy2Grp/Desc0In FY 2018, 300+ million treatments were approved for onchocerciasis control and elimination in 24 African countries and in Brazil and Venezuela. Program downscaling Onchocerciasis has been eliminated in four of the six endemic countries (Brazil, Colombia, Ecuador, Guatemala, Mexico, and Venezuela) in the Americas. Only the Yanomami Indian region overlapping Brazil and Venezuela remains - though this is a challenge given the political climate and nomadic lifestyle of the target population. In Uganda, one additional focus stopped treatment in FY 2018 in Uganda where 16 out of the 17 endemic foci have completed or are under post-treatment surveillance for onchocerciasis. Plateau and Nasarawa states in Nigeria stopped treatment for onchocerciasis, which is a remarkable achievement in one of the most heavily endemic countries. In Ethiopia, treatment was stopped in Metema Focus, Amhara State, which shares a border with Sudan. National onchocerciasis Elimination Committees (NOECs) are currently established in 17 out of the 29 endemic countries. The Mectizan Donation Program facilitated cross-country participation in NOEC meetings by supporting travel for NOEC members to attend meetings in other countries. Further, NOEC chairs from four countries in Africa participated in the Fall Mectizan Expert Committee Meeting. Lymphatic Filariasis By the end of FY 2018, 257.7 million treatments of Mectizan and albendazole were approved for the elimination lymphatic filariasis (LF) in 23 African countries. Since the inception of the program in 2000, treatment for LF has stopped in 468 implementation units. Downscaling continues in a number of African countries where 118 million individuals no longer need treatment with Mectizan and albendazole in Benin, Burkina Faso, Cameroon, Ghana, Malawi, Mali, Niger, Nigeria, Tanzania, Togo, Uganda and Yemen. Twenty million of these will continue to receive Mectizan treatment for onchocerciasis. The donation of albendazole and Mectizan was expanded in FY 2018 to include countries outside of Africa to accelerate elimination of LF. Kenya, India, Samoa, American Samoa and Tuvalu began implementing the new World Health Organization's triple therapy strategy, which includes Mectizan and albendazole.
IRS990/ProgSrvcAccomActy2Grp/ExpenseAmt0317591250
IRS990/ProgSrvcAccomActy2Grp/GrantAmt00
IRS990/ProgSrvcAccomActy2Grp/RevenueAmt0317591250
IRS990/ProgSrvcAccomActy3Grp/Desc0In FY 2018, The Center for Vaccine Equity made substantial progress in existing program areas, and expanded its role in current programs and added new program areas. Polio Eradication Support In support of Global Polio Eradication (GPEI), the Center successfully concluded a 2-year effort assisting 16 priority countries with planning for the transition of polio related financial and technical assets to country ministries. The Center's work in support of Polio Emergency Operations Management continues to grow with funding provided to establish an emergency outbreak response team. The team will support the Centers for Disease Control and Prevention (CDC) and other GPEI partners in high-priority surveillance and outbreak response activities around the globe. Serving as the secretariat for the US Polio National Certification Committee, CVE convened a meeting of the committee and submitted a report on the status of US containment to the Regional Certification Committee. The Polio Antiviral Initiative (PAI), the Center's antiviral development program, began a Phase 1 clinical study of the antiviral V-7404, one of two antiviral compounds with different mechanisms of action being developed in the program. The other antiviral, pocapavir, has been administered on a compassionate use basis to treat immune deficient individuals who are excreting poliovirus for prolonged periods. Influenza In its fifth year of operation, the Partnership for Influenza Vaccine Introduction (PIVI) extended its impact to its 14th country partner receiving vaccine, financial and/or technical support. The Partnership donated ~800,000 doses of influenza vaccine in FY 2018 and provided ~$200,000 in direct financial support to national influenza programs for capacity building activities. The project team is completing work on a dossier for use by National Immunization Technical Advisory Groups that provides guidance on the burden of disease and appropriate use of influenza vaccines. The Global Funders Consortium for Universal Influenza Vaccine Development initiated plans to establish a platform to track and provide accurate information about next generation influenza vaccines. The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota has been contracted to collaborate with the Unifluvac Working Group in compiling and curating an open-access database of universal influenza vaccine candidates and technologies currently in development. Hepatitis With the support of the CDC, The Center began development of a coalition to accelerate progress toward the elimination of viral hepatitis, the leading cause of liver cancer and death for millions of people around the world. The Coalition for Global Hepatitis Elimination is bringing together public and private partners to forge consensus on elimination goals, share knowledge and experience among implementing programs, provide technical assistance, generate new knowledge through operational research, and advocate for viral hepatitis elimination. The coalition will operate as a technical hub modeled after other Task Force for Global Health disease elimination programs. Scientific Conference Management In FY 2018, The Center supported CDC as a co-conference organizer in managing the May National Immunization Conference, and the August International Conference on Emerging Infectious Diseases. The conferences were attended by 3,000 public health professionals and research scientists.
IRS990/ProgSrvcAccomActy3Grp/ExpenseAmt04448907
IRS990/ProgSrvcAccomActy3Grp/GrantAmt00
IRS990/ProgSrvcAccomActy3Grp/RevenueAmt04448907
IRS990/ProhibitedTaxShelterTransInd00
IRS990/PYBenefitsPaidToMembersAmt00
IRS990/PYContributionsGrantsAmt02619112431
IRS990/PYExcessBenefitTransInd00
IRS990/PYGrantsAndSimilarPaidAmt02619112431
IRS990/PYInvestmentIncomeAmt00
IRS990/PYOtherExpensesAmt00
IRS990/PYOtherRevenueAmt00
IRS990/PYProgramServiceRevenueAmt00
IRS990/PYRevenuesLessExpensesAmt00
IRS990/PYSalariesCompEmpBnftPaidAmt00
IRS990/PYTotalExpensesAmt02619112431
IRS990/PYTotalProfFndrsngExpnsAmt00
IRS990/PYTotalRevenueAmt02619112431
IRS990/QuidProQuoContributionsInd00
IRS990/RcvblFromDisqualifiedPrsnGrp/BOYAmt00
IRS990/RcvblFromDisqualifiedPrsnGrp/EOYAmt00
IRS990/RcvFndsToPayPrsnlBnftCntrctInd00
IRS990/ReceivablesFromOfficersEtcGrp/BOYAmt00
IRS990/ReceivablesFromOfficersEtcGrp/EOYAmt00
IRS990/ReconcilationRevenueExpnssAmt00
IRS990/RegularMonitoringEnfrcInd01
IRS990/RelatedEntityInd01
IRS990/RelatedOrganizationCtrlEntInd00
IRS990/RelatedOrganizationsAmt00
IRS990/RentalIncomeOrLossGrp/PersonalAmt00
IRS990/RentalIncomeOrLossGrp/RealAmt00
IRS990/ReportInvestmentsOtherSecInd00
IRS990/ReportLandBuildingEquipmentInd00
IRS990/ReportOtherAssetsInd00
IRS990/ReportOtherLiabilitiesInd00
IRS990/ReportProgramRelatedInvstInd00
IRS990/RevenueAmt01821698495
IRS990/SavingsAndTempCashInvstGrp/BOYAmt00
IRS990/SavingsAndTempCashInvstGrp/EOYAmt00
IRS990ScheduleA/Form990SchASupportingOrgGrp/Contribution35ControlledInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ContributionControllerInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ContributionFamilyInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ControlledDisqualifiedPrsnInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/DisqualifiedPrsnControllIntInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/DisqualifiedPrsnOwnrIntInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ExcessBusinessHoldingsRulesInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ListedByNameGoverningDocInd01
IRS990ScheduleA/Form990SchASupportingOrgGrp/LoanDisqualifiedPersonInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/OrganizationChangeSuprtOrgInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/PaymentSubstantialContribtrInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SupportedOrgNotOrganizedUSInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SupportedOrgSectionC456Ind00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SupportNonSupportedOrgInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SuprtOrgNoIRSDeterminationInd00
IRS990ScheduleA/Form990SchAType1SuprtOrgGrp/OperateBenefitNonSuprtOrgInd00
IRS990ScheduleA/Form990SchAType1SuprtOrgGrp/PowerAppointMajorityDirTrstInd01
IRS990ScheduleA/OtherSupportSumAmt00
IRS990ScheduleA/SupportedOrganizationsCnt01
IRS990ScheduleA/SupportedOrganizationsTotalCnt01
IRS990ScheduleA/SupportedOrgInformationGrp/EIN0581698648
IRS990ScheduleA/SupportedOrgInformationGrp/GoverningDocumentListedInd01
IRS990ScheduleA/SupportedOrgInformationGrp/OrganizationTypeCd07
IRS990ScheduleA/SupportedOrgInformationGrp/OtherSupportAmt00
IRS990ScheduleA/SupportedOrgInformationGrp/SupportAmt00
IRS990ScheduleA/SupportedOrgInformationGrp/SupportedOrganizationName/BusinessNameLine1Txt0THE TASK FORCE FOR GLOBAL HEALTH INC
IRS990ScheduleA/SupportedOrgInformationGrp/SupportedOrganizationName/BusinessNameLine2Txt0Type I
IRS990ScheduleA/SupportingOrganization509a3Ind0X
IRS990ScheduleA/SupportingOrgType1Ind0X
IRS990ScheduleA/SupportSumAmt00
IRS990/ScheduleBRequiredInd01
IRS990ScheduleD/DonatedServicesAndUseFcltsAmt00
IRS990ScheduleD/DonatedServicesUseFcltsAmt00
IRS990ScheduleD/ExpensesNotReportedAmt00
IRS990ScheduleD/ExpensesNotRptFinclStmtAmt00
IRS990ScheduleD/ExpensesSubtotalAmt02143738652
IRS990ScheduleD/FederalIncomeTaxLiabilityAmt00
IRS990ScheduleD/FootnoteTextInd0X
IRS990ScheduleD/InvestmentExpensesNotIncld2Amt00
IRS990ScheduleD/InvestmentExpensesNotIncldAmt00
IRS990ScheduleD/LossesReportedAmt00
IRS990ScheduleD/NetUnrealizedGainsInvstAmt00
IRS990ScheduleD/OtherExpensesIncludedAmt00
IRS990ScheduleD/OtherExpensesNotIncludedAmt00
IRS990ScheduleD/OtherRevenueAmt00
IRS990ScheduleD/OtherRevenuesNotIncludedAmt00
IRS990ScheduleD/PriorYearAdjustmentsAmt00
IRS990ScheduleD/RecoveriesPriorYearGrantsAmt00
IRS990ScheduleD/RevenueNotReportedAmt00
IRS990ScheduleD/RevenueNotReportedFinclStmtAmt00
IRS990ScheduleD/RevenueSubtotalAmt02143738652
IRS990ScheduleD/SupplementalInformationDetail/ExplanationTxt0During December 2017, the President of the United States of America signed into law the Tax Cuts and Jobs Act. Under this Act, maximum corporate tax rates were reduced from 35% to a flat rate of 21%. The Organization's tax liability for any potential unrelated business income should not be significant. There are other changes to the tax law that may affect the Organization, but the magnitude of such changes has not been determined.
IRS990ScheduleD/SupplementalInformationDetail/FormAndLineReferenceDesc0Schedule D, Part X, Line 2
IRS990ScheduleD/TotalExpensesPerForm990Amt02143738652
IRS990ScheduleD/TotalLiabilityAmt00
IRS990ScheduleD/TotalRevenuePerForm990Amt02143738652
IRS990ScheduleD/TotalRevEtcAuditedFinclStmtAmt02143738652
IRS990ScheduleD/TotExpnsEtcAuditedFinclStmtAmt02143738652
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt013
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt10
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt20
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt30
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt40
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt01
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt10
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt20
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt30
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt40
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt02127614405
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt13230921
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt21825579
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt31646907
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt49420840
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt0Sub-Saharan Africa
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt1East Asia and the Pacific
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt2South Asia
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt3Europe (including Iceland and Greenland)
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt4Middle East and North Africa
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt0Donated pharmaceuticals
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt1Donated pharmaceuticals
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt2Donated pharmaceuticals
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt3Donated pharmaceuticals
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt4Donated pharmaceuticals
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt0Program Services
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt1Program Services
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt2Program Services
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt3Program Services
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt4Program Services
IRS990ScheduleF/BoycottCountriesInd00
IRS990ScheduleF/ForeignCorpOwnershipInd00
IRS990ScheduleF/ForeignPartnershipInd00
IRS990ScheduleF/GrantRecordsMaintainedInd01
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt00
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt10
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt20
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt30
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt40
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/DescriptionOfNonCashAsstTxt0Donated pharmaceuticals
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/DescriptionOfNonCashAsstTxt1Donated pharmaceuticals.
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/DescriptionOfNonCashAsstTxt2Donated pharmaceuticals
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/DescriptionOfNonCashAsstTxt3Donated vaccines
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/DescriptionOfNonCashAsstTxt4Donated pharmaceuticals
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt02127614405
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt13230921
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt21646907
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt31825579
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt49420840
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt0To treat trachoma, lymphatic filariasis and sleeping sickness
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt1For the treatment of lymphatic filariasis and viruses
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt2Vaccines for the treatment of viruses
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt3Vaccines for treatment
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt4For the treatment of trachoma
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt0Sub-Saharan Africa
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt1East Asia and the Pacific
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt2Europe (including Iceland and Greenland)
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt3South Asia
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt4Middle East and North Africa
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/ValuationMethodUsedDesc0Lower of donor's valuation and/or selected market pharmacies
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/ValuationMethodUsedDesc1Lower of donor's valuation and/or selected market pharmacies
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/ValuationMethodUsedDesc2Lower of donor's valuation and/or selected market pharmacies
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/ValuationMethodUsedDesc3Lower of donor's valuation and/or selected market pharmacies
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/ValuationMethodUsedDesc4Lower of donor's valuation and/or selected market pharmacies
IRS990ScheduleF/InterestInForeignTrustInd00
IRS990ScheduleF/PassiveForeignInvestmestCoInd00
IRS990ScheduleF/SupplementalInformationDetail/ExplanationTxt0The In-Kind Contributions are shipped directly by the donor to the countries where they are needed. Global Health Solutions obtains the shipping documents for processing in the accounting system. Occasional site visits are carried out in some countries to access and evaluate the impact of the program activities. In our Ethiopia country office, an audit firm is appointed to ensure that things are done in compliance to required rules and regulations.
IRS990ScheduleF/SupplementalInformationDetail/FormAndLineReferenceDesc0Schedule F, Part I, Line 2
IRS990ScheduleF/Total501c3OrgCnt05
IRS990ScheduleF/TotalEmployeeCnt013
IRS990ScheduleF/TotalOfficeCnt01
IRS990ScheduleF/TotalOtherOrgCnt05
IRS990ScheduleF/TotalSpentAmt02143738652
IRS990ScheduleF/TransferToForeignCorpInd00
IRS990ScheduleJ/AnyNonFixedPaymentsInd00
IRS990ScheduleJ/CompBasedOnRevenueOfFlngOrgInd00
IRS990ScheduleJ/CompBsdNetEarnsFlngOrgInd00
IRS990ScheduleJ/CompBsdNetEarnsRltdOrgsInd00
IRS990ScheduleJ/CompBsdOnRevRelatedOrgsInd00
IRS990ScheduleJ/EquityBasedCompArrngmInd00
IRS990ScheduleJ/InitialContractExceptionInd00
IRS990/ScheduleJRequiredInd01
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt00
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt10
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt20
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt30
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt40
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BonusFilingOrganizationAmount00
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BonusFilingOrganizationAmount10
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BonusFilingOrganizationAmount20

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2018 • Form 990Detailed filing. Detailed filing data is available for this year.

Open filing
Assets
$0
Liabilities
$0
Net assets
$0
Revenue
$2,143,738,652
Expenses
$2,143,738,652
Net income
$0
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Facts available. Structured filing facts are available, but richer extracted sections are limited.$0.00$0.00$0.00$511$511$0.00
2023Summary only. Only limited summary data is available for this year.$0.00$0.00$0.00$629$629$0.00
2022XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.00$0.00$0.00$632$632$0.00
2021Facts available. Structured filing facts are available, but richer extracted sections are limited.$0.00$0.00$0.00$961$961$0.00
2020XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.00$0.00$0.00$847$847$0.00
2019XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.00$0.00$0.00$2,522$2,522$0.00
2018Detailed filing. Detailed filing data is available for this year.$0.00$0.00$0.00$2,144$2,144$0.00
2017Facts available. Structured filing facts are available, but richer extracted sections are limited.$0.00$0.00$0.00$2,619$2,619$0.00
2016XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.00$0.00$0.00$3,126$3,129$2.35
2015Summary only. Only limited summary data is available for this year.$2.35$0.00$2.35$1,609$1,609$0.00
2014Detailed filing. Detailed filing data is available for this year.$2.35$0.00$2.35$1,791$1,791$0.00
2013Summary only. Only limited summary data is available for this year.$2.35$0.00$2.35$1,574$1,574$0.00
2012Facts available. Structured filing facts are available, but richer extracted sections are limited.$2.35$0.00$2.35$1,634
2011Facts available. Structured filing facts are available, but richer extracted sections are limited.$2.36$0.00$2.36$1,131
2010Facts available. Structured filing facts are available, but richer extracted sections are limited.$2.36$0.00$2.36$1,121
Peer Organizations

Similar nonprofits based on the same Siviq industry and scale cohort. 2018 filings • 501(c)3 • $1B+ nonprofits